U: The Mind Company reports Alzheimer’s study showed major brain connectivity gains

By AI, Created 10:57 AM UTC, May 20, 2026, /AGP/ – U: The Mind Company says a peer-reviewed fMRI study in five Alzheimer’s patients found marked increases in memory and language network activity after 12 weeks of daily non-invasive stimulation. The Ohio company says the wearable headset caused no serious adverse events and is now advancing medical devices for Alzheimer’s and Parkinson’s disease through the FDA process.

Why it matters: - U: The Mind Company says the study suggests a non-surgical approach may help restore brain connectivity affected by Alzheimer’s disease. - The results matter because current Alzheimer’s drugs mainly address symptoms, while the company’s approach targets network function in the brain. - The study used an externally worn device, which avoids surgery or implants.

What happened: - U: The Mind Company announced peer-reviewed results from an Alzheimer’s disease study published in IntechOpen’s 2024 anthology New Insights in Brain-Computer Interface Systems. - Five patients diagnosed with Alzheimer’s disease received daily sessions of amplitude-modulated transcranial pulsed current stimulation, or am-tPCS. - The treatment was delivered through a lightweight headset worn on the scalp. - The protocol lasted 12 weeks and used 20 minutes of stimulation per day. - Resting-state fMRI scans were collected at baseline and at the end of the study. - No serious adverse events were reported in any patient.

The details: - Brain activity in the left hippocampus increased by 580%. - The temporal pole showed a 5,400% increase in functional activation. - The posterior middle temporal gyrus increased by 3,100%. - New functional connections appeared in the region tied to planning and decision-making, rising from zero to 36 voxels on the left and from zero to 92 voxels on the right. - The company said that pattern suggests network reorganization rather than only stimulation of existing pathways. - The default mode network showed improved inter-hemispheric coordination after treatment. - The salience network also showed improved inter-hemispheric coordination. - The device delivers electrical signals through the scalp to the prefrontal cortex. - The company says the signal patterns are protected by two granted U.S. patents, with additional patents pending. - U: The Mind Company was founded in 2018 and is headquartered in Cleveland, Ohio. - Research collaborators include Mayo Clinic, MIT, and Johns Hopkins’ researchers. - Full study findings are available here.

Between the lines: - The findings are early and based on a very small sample, so they are more signal than proof. - The company is positioning the technology as a disease-targeting platform, not just a wellness product. - The focus on connectivity and network restoration reflects a broader push in neuroscience toward circuit-level interventions. - Founder and CEO Mohammed Abouelsoud said the fMRI findings show the brain is “stimulated and more importantly reorganized.”

What’s next: - U: The Mind Company is advancing two medical devices, Sphere for Parkinson’s disease and Axis for Alzheimer’s disease, through the FDA approval process. - The company is also selling a consumer wellness device, NeuroEdge, for focus and cognitive performance. - U: The Mind Company is targeting FDA clearance in 2028. - The company says its 12-week protocol mirrors the timeline of natural neuroplasticity.

The bottom line: - U: The Mind Company says its wearable brain-stimulation platform produced large fMRI changes in a small Alzheimer’s study, and the company now wants to turn that early evidence into cleared medical devices.